Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
about
The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cellsThe immunohistochemical localisation of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromasContinuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinomaThe role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review.Utility of (99m)Tc-Hynic-TOC in 131I Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels.Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.Treatment of Zollinger-Ellison syndrome.Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors.Canine gastrinoma: a case study and literature review of therapeutic options.Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas.Somatostatin stimulates menin gene expression by inhibiting protein kinase A.Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.Malignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature.Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified?Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation.Transient receptor potential channel TRPM8 agonists stimulate calcium influx and neurotensin secretion in neuroendocrine tumor cells.Insulin-like growth factor-1 increases intracellular calcium concentration in human primary neuroendocrine pancreatic tumor cells and a pancreatic neuroendocrine tumor cell line (BON-1) via R-type Ca2+ channels and regulates chromogranin a secretionInterferon-alpha: regulatory effects on cell cycle and angiogenesis.Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells.Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration.Be careful before prescribing warfarin and octreotide together: a new drug-drug interaction report.Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas.Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire.Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.
P2860
Q28484664-AF4E664E-EF72-4070-A2DE-76D414079991Q30502907-127D4C07-29D6-4BB7-9746-F29FEBD79038Q33514751-C0226AB2-6DE6-4CDF-A74D-9710F7EEB039Q34484273-4EEBDCDC-10B9-4693-92EF-7C123E52CC23Q34564262-4264DA0E-8959-4504-B8AA-CD0B0BC1C293Q34769975-3B13BA31-2314-4ED2-BB74-3FC70D587894Q35178055-8ACDE9F9-D814-42B4-A444-5BD7C982DE25Q35682070-A247D4E6-2399-43BD-A2DF-C6480027F344Q35755390-791DC5B3-CE8A-450F-B524-F2C5F7C27155Q35999552-2669F839-CEDE-46B9-AD31-4F7E6F40BF37Q36285347-47EAEE5A-B844-4DF7-BBCF-3FB4C7142CC4Q36480150-06A5BA9F-086D-463A-9430-15A576C47190Q36617833-93F834AA-DDE0-4A20-B3A8-362D34A7C087Q36816158-2AF263D6-A0D9-40F8-A459-BC3C15575988Q36956111-16A146E0-8668-429D-B52A-AFEA1B42F496Q37483944-120B4485-B7DE-4427-AC5F-8D28A7B28B65Q37682771-1F412A8B-4330-42D4-BB5A-00DAEF217EB6Q38754421-C88BBE7F-D388-48F9-8393-D7AAD0A28FA0Q38903218-573B8FC3-14E7-4898-9D31-E7E4A6223F7FQ40147127-5E08ECF8-ED2A-4EDF-8CBF-BF34A066E250Q40327233-DF80D769-C49D-4754-8987-F902CC5F7428Q40505312-221CE974-0314-49BC-9493-EBAAA12AF6EBQ40706828-1DA3D6CD-2772-4230-A4B6-163F1738D297Q40727776-D6B9EACE-C455-424A-B6CB-CDB20F03D6D8Q42742462-36A08056-69A4-4758-9C9F-AA19788374F3Q43121154-9EE3E8E8-EA5F-4E3C-97CB-794324AA054AQ43921041-2726D77D-211C-4F01-85A0-8591298604DBQ44425913-664C134E-DA48-4442-A20C-DC856628E10FQ50471116-B4AFDD9F-87C9-4E2C-B393-831F0FA3849DQ51479301-071764C6-39B2-4CB0-BB79-6CB9818FF734
P2860
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@ast
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@en
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@nl
type
label
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@ast
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@en
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@nl
prefLabel
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@ast
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@en
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@nl
P2093
P356
P1433
P1476
Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
@en
P2093
P356
10.1159/000051861
P478
62 Suppl 1
P577
2000-01-01T00:00:00Z